

OLON - FINAL DOSAGE FORMS

17 July 2019

FDF-CTD DOSSIER- available for LICENSING

INN	Dosage Form	Therapeutic Class	Available Dossier	Reference Product
Acitretin	Capsule 7.5-10-12.5-25 mg	Retinoid (Antipsoriatic)	EU-RoW	Soriatane
Clofarabine	Vial-Liquid 20 mg	Antineoplastic	US-EU-RoW	Clolar/Evoltra
Deferoxamine mesylate	Vial-Lyo 500-2,000 mg	Iron chelating agent	US-EU-RoW	Desferal
Teriflunomide	Film-Coated Tablet 7-14 mg	Agents for multiple sclerosis	US-EU-RoW	Aubagio
Valgancyclovir	Film-Coated Tablet 450 mg	Antiviral	EU-RoW	Valcyte

FDF-Co-development opportunities

INN	Dosage Form	Therapeutic Class	Olon Offer	Reference Product
Apalutamide	Film-coated tablet 60 mg	Antineoplastic	NI API	Erleada
Daptomycin	Vial-Lyo 350-500 mg	Antibacterial	US-EU-RoW	Cubicin
Enzalutamide	Soft gel capsules 40 mg	Antineoplastic	Proprietary process	Xtandi
Lenvatinib mesylate	Capsule 4-10 mg	Antineoplastic	Second wave for US	Lenvima
Letermovir	Tablet 240 mg and 480 mg Injectable 240 mg/12 mL and 480 mg/24 mL	Antiviral	Proprietary process	Prevymis
Lifitegrast	5% Ophthalmic drops	Dry eyes disease	Proprietary innovative manufacturing process	Xiidra
Nintedanib esylate	Soft-Gel 100-150 mg	Antineoplastic, IPF	Second wave for US	Ofev
Olaparib	Film-Coated Tablet 100-150 mg	Antineoplastic	NI API	Lymparza
Teduglutide	Vial-Lyo 5 mg	Short Bowel Syndrome (SBS)	Recombinant API	Gattex
Venetoclax	Film-coated Tablet 10-50-100mg	Antineoplastic	NI form and RoS	Venclexta